Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:05 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,391 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study Pill Clear all
Completed Phase 2 Interventional Results available

Study of the Medication Prazosin for Alcohol Dependence

NCT00762710
View directory record Official record
Conditions
Alcoholism
Interventions
Prazosin medication, Placebo medication
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Nov 3, 2026, 5:05 PM EST
Completed Phase 4 Interventional Results available

Chewed Versus Integral Pill of Ticagrelor

NCT03708588
View directory record Official record
Conditions
Percutaneous Coronary Intervention
Interventions
Ticagrelor
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 89 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Nov 3, 2026, 5:05 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Ovulation Incidence in Oral Contraceptive Users

NCT03106454
View directory record Official record
Conditions
Contraception, Ovulation
Interventions
Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate, Norethindrone
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Nov 3, 2026, 5:05 PM EST
Terminated Phase 4 Interventional

Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist

NCT01776203
View directory record Official record
Conditions
Dysfunctional Uterine Bleeding
Interventions
Medroxyprogesterone 17-Acetate
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Nov 3, 2026, 5:05 PM EST
Suspended Phase 3 Interventional

VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)

NCT04363203
View directory record Official record
Conditions
SARS-CoV-2, COVID-19
Interventions
Hydroxychloroquine, Azithromycin, Placebo oral tablet
Drug
Lead sponsor
Salomeh Keyhani MD
Federal
Eligibility
216 Months and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Nov 3, 2026, 5:05 PM EST
Completed Not applicable Interventional Results available

Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat

NCT01971203
View directory record Official record
Conditions
Major Depressive Disorder, Generalized Anxiety Disorder
Interventions
seroquel xr, CBT
Drug · Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Nov 3, 2026, 5:05 PM EST
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Ramipril for the Treatment of Oligospermia

NCT01856361
View directory record Official record
Conditions
Oligospermia, Teratospermia, Asthenozoospermia, Male Infertility
Interventions
Ramipril, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Nov 3, 2026, 5:05 PM EST
Completed Phase 2 Interventional Results available

Exenatide in Extreme Pediatric Obesity

NCT01237197
View directory record Official record
Conditions
Obesity
Interventions
Exenatide, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 19 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 12, 2014 · Synced Nov 3, 2026, 5:05 PM EST
Completed Not applicable Interventional Results available

Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy

NCT01521546
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
eplerenone, placebo
Drug
Lead sponsor
Subha Raman
Other
Eligibility
7 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Nov 3, 2026, 5:05 PM EST
Withdrawn Phase 2 Interventional

Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis

NCT01141296
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
fenofibrate, placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
21 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Miami, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Nov 3, 2026, 5:05 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Brain and Stress Study

NCT06044090
View directory record Official record
Conditions
Stress, Psychological, Motivation
Interventions
Minocycline, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
25 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Nov 3, 2026, 5:05 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers

MAPS PrEP Van Study

NCT06908252
View directory record Official record
Conditions
HIV Infection
Interventions
Pre-Exposure Prophylaxis (PrEP)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Nov 3, 2026, 5:05 PM EST
Recruiting Phase 1Phase 2 Interventional

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

NCT04086485
View directory record Official record
Conditions
Gastroenteropancreatico Tumors, Neuroendocrine Tumors, Neuroendocrine Neoplasms
Interventions
Lu-177-DOTATATE, Olaparib, Ga dotatate scanning, FDG-PET scanning, Amino Acid infusion
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 3, 2026, 5:05 PM EST
Completed Phase 2 Interventional

Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer

NCT02531932
View directory record Official record
Conditions
Breast Cancer
Interventions
Carboplatin, Everolimus
Drug
Lead sponsor
Amy Tiersten
Other
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Nov 3, 2026, 5:05 PM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

NCT01651000
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
Interventions
CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
Drug · Other
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bannockburn, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Nov 3, 2026, 5:05 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female Volunteers

NCT00504816
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions
GSK189075, Brevicon
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Nov 3, 2026, 5:05 PM EST
Completed Phase 2 Interventional Results available

Study of Losartan in the Treatment of NAFLD in Children

NCT01913470
View directory record Official record
Conditions
NAFLD
Interventions
Losartan
Drug
Lead sponsor
Miriam Vos, MD
Other
Eligibility
11 Years to 19 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Nov 3, 2026, 5:05 PM EST
Recruiting Not applicable Interventional

Studying Melatonin and Recovery in Teens

NCT06093477
View directory record Official record
Conditions
Juvenile; Scoliosis, Scoliosis Idiopathic, Scoliosis; Adolescence, Scoliosis;Congenital, Kyphosis, Spondylolisthesis, Pectus Surgery, Hip Surgery
Interventions
Fast-Dissolve Melatonin Pill, Fast-Dissolve Placebo Pill
Dietary Supplement · Other
Lead sponsor
Stanford University
Other
Eligibility
12 Years to 18 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 3, 2026, 5:05 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Leukotriene Antagonism in Recruitment of CD49d Expressing Neutrophils in Atopic Subjects

NCT03039101
View directory record Official record
Conditions
Nasal Allergy
Interventions
Nasal lavage, Nasal allergen challenge, Epicutaneous skin testing, Peripheral blood, Montelukast 10Mg Tablet, Placebo Oral Tablet
Procedure · Drug
Lead sponsor
Mitchell Grayson
Other
Eligibility
21 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Nov 3, 2026, 5:05 PM EST
Completed Not applicable Interventional Results available

In-person vs. Remote Wellness Support

NCT04526067
View directory record Official record
Conditions
Depressive Disorder, Major, Bipolar Disorder, Schizo Affective Disorder, Schizophrenia
Interventions
CAT, R-CAT
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Nov 3, 2026, 5:05 PM EST
Completed Phase 2 Interventional

A Study of Cabergoline for the Treatment of Cocaine Dependence - 1

NCT00033111
View directory record Official record
Conditions
Cocaine-Related Disorders, Substance-Related Disorders
Interventions
Cabergoline, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 99 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
2
States / cities
Torrance, California • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Nov 3, 2026, 5:05 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Treatment of Pneumocystis in COPD (the TOPIC Study)

NCT05418777
View directory record Official record
Conditions
COPD Exacerbation Acute
Interventions
Trimethoprim Sulfamethoxazole, Placebo
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
40 Years to 89 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Nov 3, 2026, 5:05 PM EST
Completed Phase 4 Interventional

Study of Bronchodilation Effects of Cetirizine

NCT01781507
View directory record Official record
Conditions
Allergic Rhinitis, Asthma
Interventions
Cetirizine, Placebo
Drug
Lead sponsor
California Allergy and Asthma Medical Group, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Nov 3, 2026, 5:05 PM EST
Completed Phase 3 Interventional Results available

A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease

NCT01176240
View directory record Official record
Conditions
Orthostatic Hypotension, Parkinson's Disease
Interventions
Droxidopa, Placebo
Drug · Other
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
60
States / cities
Alabaster, Alabama • Gilbert, Arizona • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Nov 3, 2026, 5:05 PM EST